<p>Lineage Cell Therapeutics, Inc.（纽约证券交易所代码：LCTX - 获取免费报告）周二上涨了 4.7%。该公司的股价最高达到 1.82 美元，最后交易价格为 1.80 美元。在交易过程中，约有 1,331,886 股成交，较日均成交量 1,228,101 股增加了 8%。该股票此前收盘价为 1.72 美元。</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师对 LCTX 股票发布了报告。HC Wainwright 在 11 月 24 日的研究报告中重申了对 Lineage Cell Therapeutics 的 “买入” 评级，并给出了 9.00 美元的目标价。D. Boral Capital 在 11 月 25 日的报告中重申了 “买入” 评级，并给出了 2.00 美元的目标价。根据 MarketBeat 的数据，四位股票研究分析师对该股票给予了 “买入” 评级，目前该股票的共识评级为 “买入”，共识目标价为 4.25 美元。</p>
<p><strong>阅读我们对 LCTX 的最新分析</strong></p>
<h2>Lineage Cell Therapeutics 股票表现</h2>
<p>该公司 50 日移动平均线为 1.74 美元，200 日移动平均线为 1.35 美元。该股票的市值为 4.1459 亿美元，市盈率为-6.21，贝塔值为 1.78。</p>
<p>Lineage Cell Therapeutics（纽约证券交易所代码：LCTX - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告本季度每股收益为（0.13 美元），低于市场共识预期的（0.02 美元）11 美分。该公司本季度的收入为 368 万美元，而分析师预期为 230 万美元。Lineage Cell Therapeutics 的股本回报率为-72.02%，净利润率为-625.53%。研究分析师平均预测 Lineage Cell Therapeutics, Inc.在当前财政年度的每股收益为-0.12 美元。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Citizens Financial Group Inc. RI 在第三季度新购入了 Lineage Cell Therapeutics 的股份，价值约 25,000 美元。Kapitalo Investimentos Ltda 在第二季度购买了 Lineage Cell Therapeutics 的新股份，价值约 25,000 美元。Jump Financial LLC 在第二季度新购入了 Lineage Cell Therapeutics 的股份，价值约 28,000 美元。Cannon Global Investment Management LLC 在第二季度新购入了 Lineage Cell Therapeutics 的股份，价值约 30,000 美元。最后，Integrity Alliance LLC 在第二季度将其在 Lineage Cell Therapeutics 的股份增加了 75.0%。Integrity Alliance LLC 目前拥有该公司 35,000 股股票，价值 32,000 美元，此前在上个季度又购买了 15,000 股。62.47% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>关于 Lineage Cell Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Lineage Cell Therapeutics, Inc.是一家临床阶段的生物技术公司，开发针对美国及国际上未满足医疗需求的新型细胞疗法。该公司开发的 OpRegen 是一种异体视网膜色素上皮细胞替代疗法，目前正在进行针对干性年龄相关性黄斑变性的 2a 期临床试验；OPC1 是一种异体少突胶质细胞前体细胞疗法，目前正在进行针对颈部脊髓损伤的 1/2a 期多中心临床试验；VAC 是一种异体癌症免疫疗法，使用抗原呈递树突细胞，目前正在进行针对非小细胞肺癌的 I 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Lineage Cell Therapeutics</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个聪明的买入</li>
<li>CD 计算器：定期存款计算器</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lineage Cell Therapeutics 吗？</h2>
<p>在你考虑投资 Lineage Cell Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Lineage Cell Therapeutics 并不在名单上。</p>
<p>虽然 Lineage Cell Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

LCTX

<p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) 的股价上涨了 4.7%，最高交易价达到 $1.82。分析师对该股票给予了一致的 “买入” 评级，目标价为 $4.25。公司报告的季度每股收益为 ($0.13)，未达到预期，但收入超出预期。机构投资者表现出兴趣，62.47% 的股份由他们持有。该公司正在开发满足未满足医疗需求的疗法，包括治疗黄斑变性和脊髓损伤的治疗方案</p>

<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was up 4.7% on Tuesday . The company traded as high as $1.82 and last traded at $1.80. Approximately 1,331,886 shares traded hands during trading, an increase of 8% from the average daily volume of 1,228,101 shares. The stock had previously closed at $1.72.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc.（纽约证券交易所代码：LCTX - 获取免费报告）周二上涨了 4.7%。该公司的股价最高达到 1.82 美元，最后交易价格为 1.80 美元。在交易过程中，约有 1,331,886 股成交，较日均成交量 1,228,101 股增加了 8%。该股票此前收盘价为 1.72 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts have issued reports on LCTX shares. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. D. Boral Capital restated a &#34;buy&#34; rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, November 25th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $4.25.</p>
<div class="lb-trans"><p>几位股票分析师对 LCTX 股票发布了报告。HC Wainwright 在 11 月 24 日的研究报告中重申了对 Lineage Cell Therapeutics 的 “买入” 评级，并给出了 9.00 美元的目标价。D. Boral Capital 在 11 月 25 日的报告中重申了 “买入” 评级，并给出了 2.00 美元的目标价。根据 MarketBeat 的数据，四位股票研究分析师对该股票给予了 “买入” 评级，目前该股票的共识评级为 “买入”，共识目标价为 4.25 美元。</p>
</div><p><strong>Read Our Latest Analysis on LCTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 LCTX 的最新分析</strong></p>
</div><h2>Lineage Cell Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 股票表现</h2>
</div><p>The business has a 50-day moving average of $1.74 and a 200-day moving average of $1.35. The stock has a market capitalization of $414.59 million, a price-to-earnings ratio of -6.21 and a beta of 1.78.</p>
<div class="lb-trans"><p>该公司 50 日移动平均线为 1.74 美元，200 日移动平均线为 1.35 美元。该股票的市值为 4.1459 亿美元，市盈率为-6.21，贝塔值为 1.78。</p>
</div><p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $3.68 million for the quarter, compared to analyst estimates of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 72.02% and a negative net margin of 625.53%. On average, research analysts predict that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics（纽约证券交易所代码：LCTX - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告本季度每股收益为（0.13 美元），低于市场共识预期的（0.02 美元）11 美分。该公司本季度的收入为 368 万美元，而分析师预期为 230 万美元。Lineage Cell Therapeutics 的股本回报率为-72.02%，净利润率为-625.53%。研究分析师平均预测 Lineage Cell Therapeutics, Inc.在当前财政年度的每股收益为-0.12 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Citizens Financial Group Inc. RI acquired a new stake in shares of Lineage Cell Therapeutics during the third quarter worth about $25,000. Kapitalo Investimentos Ltda purchased a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $25,000. Jump Financial LLC acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $28,000. Cannon Global Investment Management LLC acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter worth approximately $30,000. Finally, Integrity Alliance LLC. grew its stake in shares of Lineage Cell Therapeutics by 75.0% in the 2nd quarter. Integrity Alliance LLC. now owns 35,000 shares of the company's stock valued at $32,000 after purchasing an additional 15,000 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Citizens Financial Group Inc. RI 在第三季度新购入了 Lineage Cell Therapeutics 的股份，价值约 25,000 美元。Kapitalo Investimentos Ltda 在第二季度购买了 Lineage Cell Therapeutics 的新股份，价值约 25,000 美元。Jump Financial LLC 在第二季度新购入了 Lineage Cell Therapeutics 的股份，价值约 28,000 美元。Cannon Global Investment Management LLC 在第二季度新购入了 Lineage Cell Therapeutics 的股份，价值约 30,000 美元。最后，Integrity Alliance LLC 在第二季度将其在 Lineage Cell Therapeutics 的股份增加了 75.0%。Integrity Alliance LLC 目前拥有该公司 35,000 股股票，价值 32,000 美元，此前在上个季度又购买了 15,000 股。62.47% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>About Lineage Cell Therapeutics</h2>
<div class="lb-trans"><h2>关于 Lineage Cell Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc.是一家临床阶段的生物技术公司，开发针对美国及国际上未满足医疗需求的新型细胞疗法。该公司开发的 OpRegen 是一种异体视网膜色素上皮细胞替代疗法，目前正在进行针对干性年龄相关性黄斑变性的 2a 期临床试验；OPC1 是一种异体少突胶质细胞前体细胞疗法，目前正在进行针对颈部脊髓损伤的 1/2a 期多中心临床试验；VAC 是一种异体癌症免疫疗法，使用抗原呈递树突细胞，目前正在进行针对非小细胞肺癌的 I 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Lineage Cell Therapeutics</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Lineage Cell Therapeutics</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个聪明的买入</li>
<li>CD 计算器：定期存款计算器</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lineage Cell Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lineage Cell Therapeutics 吗？</h2>
</div><p>Before you consider Lineage Cell Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Lineage Cell Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Lineage Cell Therapeutics 并不在名单上。</p>
</div><p>While Lineage Cell Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lineage Cell Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) 股价上涨 4.7% - 你应该购买吗？